홈 > 시장보고서 > 의약품 > 재생의학

시장보고서

상품코드

1552515

혈소판풍부혈장 시장, 규모, 점유율, 동향, 산업 분석 보고서 : 유형별, 용도별, 최종 용도별, 지역별 - 시장 예측(2024-2032년)

Platelet Rich Plasma Market Size, Share, Trends, Industry Analysis Report: By Type, By Application, By End-Use, and By Region - Market Forecast, 2024 - 2032

발행일: 2024년 08월 | 리서치사:

Polaris Market Research | 페이지 정보: 영문 116 Pages | 배송안내 : 1-2일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최신 조사에 따르면, 세계 혈소판풍부혈장 시장 규모는 2032년까지 27억 8,389만 달러에 달할 것으로 예상됩니다. 이 보고서는 현재 시장 역학에 대한 자세한 통찰력과 미래 시장 성장에 대한 분석을 제공합니다.

다중 혈소판 혈장에 대한 수요는 전 세계 다양한 의료 및 미용 분야에서 강력한 성장세를 보이고 있으며, PRP는 건염, 관절염, 스포츠 관련 부상과 같은 근골격계 부상을 포함한 다양한 증상을 치료할 수 있는 다재다능함이 그 인기에 큰 기여를 하고 있습니다. 정형외과에서 PRP는 수술 후 회복 속도를 높이고 회복 시간을 단축하기 위해 점점 더 많이 사용되고 있으며, 비침습적 치료법을 원하는 운동선수와 노년층 모두에게 어필하고 있습니다.

다중 혈소판 혈장(PRP)은 피부 회춘, 모발 복원, 상처 치유를 위한 피부과 치료로 확대되고 있으며, 비수술적 미용 개선에 대한 소비자의 관심이 그 원동력이 되고 있습니다. 또한, 골관절염과 같은 만성 질환 증가와 고령화로 인해 최소침습적 치료를 선호하는 고령화도 PRP의 채택을 더욱 촉진하고 있으며, PRP 제제의 기술 발전과 PRP의 효능을 뒷받침하는 임상적 증거는 시장 확대의 원동력으로 작용하고 있습니다.

PRP가 주류 의료 관행에 통합되고 치료 효과를 입증하는 임상 연구가 증가함에 따라 시장의 지속적인 성장에 기여하고 있습니다. PRP에 대한 인식이 높아지고 의료 서비스 제공업체들이 PRP의 잠재력을 수용함에 따라 시장은 전 세계적으로 상승세를 이어갈 것으로 보입니다.

PRP 시장 보고서의 주요 내용

순수 혈소판풍부혈장(P-PRP)은 혈소판 농도가 높고 만성질환 치료와 조직 복구 및 재생 촉진에 효과적이어서 2023년 시장을 장악했습니다.

일반 수술 카테고리는 수술 후 회복을 촉진하고 합병증을 감소시키는 PRP의 역할로 인해 가장 높은 CAGR을 나타낼 것으로 추정되며, 이는 수술 의료의 미래를 형성할 것으로 예상됩니다.

북미는 2023년 세계 PRP 시장을 장악할 것으로 예상되며, 미용 수술, 성형 수술, 스포츠 부상, 관절염 사례 및 광범위한 응용 분야로 인한 수요에 의해 강화될 것으로 보입니다.

혈소판풍부혈장(PRP) - 업계 개요
밸류체인 분석
- 혈소판풍부혈장(PRP) 시장 역학
- 성장 촉진요인과 기회
- 성장 억제요인과 과제
Porter's Five Forces
- 대체품의 위협 : 저-중
- 신규 진출업체의 위협 : 중-고
- 바이어의 교섭력 : 저-중
- 공급 기업의 교섭력 : 중-고
- 경쟁 기업간 경쟁 관계 : 중-고
PESTLE 분석
COVID-19의 영향 분석과 업계 동향

제5장 혈소판풍부혈장(PRP) 시장 : 유형별

서론
순수 혈소판 다혈장(P-PRP)
백혈구 및 혈소판 함유 혈장(L-PRP)
순수 혈소판 피브린(P-PRF)
백혈구 및 혈소판 풍부 피브린(L-PRF)

제6장 혈소판풍부혈장(PRP) 시장 : 용도별

서론
정형외과
스포츠 의학
일반외과
피부과
안과
신경학
심장병학
기타

제7장 혈소판풍부혈장(PRP) 시장 : 최종 용도별

서론
병원
클리닉
기타

제8장 혈소판풍부혈장(PRP) 시장 : 지역별

서론
북미
- 북미 : 유형별
- 북미 : 용도별
- 북미 : 최종 용도별
- 미국
- 캐나다
유럽
- 유럽 : 유형별
- 유럽 : 용도별
- 유럽 : 최종 용도별
- 프랑스
- 독일
- 영국
- 이탈리아
- 네덜란드
- 스페인
- 러시아
- 기타 유럽
아시아태평양
- 아시아태평양 : 유형별
- 아시아태평양 : 용도별
- 아시아태평양 : 최종 용도별
- 일본
- 중국
- 인도
- 말레이시아
- 인도네시아
- 한국
- 호주
- 아시아태평양 기타 국가
라틴아메리카
- 라틴아메리카 : 유형별
- 라틴아메리카 : 용도별
- 라틴아메리카 : 최종 용도별
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
중동 및 아프리카
- 중동 및 아프리카 : 유형별
- 중동 및 아프리카 : 용도별
- 중동 및 아프리카 : 최종 용도별
- 사우디아라비아
- 남아프리카공화국
- 중동 및 아프리카 나머지

제9장 경쟁 구도

주요 시장 기업 : 분류
전략적 프레임워크
벤더 구도
전략 분류
- 발매/승인/개발

제10장 기업 개요

Vivostat
Arthrex, Inc.
RegenOrthoSport
Dr PRP USA LLC
Juventix Regenerative Medical, LLC.
Terumo Cardiovascular Systems Corporation
Zimmer Biomet
Isto Biologics
APEX Biologix
Regen Lab SA

LSH 24.10.10

The global platelet rich plasma market size is expected to reach USD 2,783.89 million by 2032, according to a new study by Polaris Market Research. The report "Global Platelet Rich Plasma (PRP) Market Size, Share, Trends, Industry Analysis Report: By Type, By Application, By End-Use (Hospitals, Clinics, and Others), and By Region (North America, Europe, Asia-Pacific, Middle East & Africa, And Latin America) - Market Forecast, 2024 - 2032." gives a detailed insight into current market dynamics and provides analysis on future market growth.

The demand for platelet-rich plasma is experiencing robust growth across various medical and aesthetic fields globally. PRP's versatility in treating a wide range of conditions, including musculoskeletal injuries like tendonitis, arthritis, and sports-related injuries, has significantly contributed to its popularity. In orthopedics, PRP is increasingly used to expedite healing and reduce recovery times post-surgery, appealing to both athletes and aging populations alike seeking non-invasive treatment options.

PRP's applications extend into dermatology for skin rejuvenation, hair restoration, and wound healing, driven by consumer interest in non-surgical cosmetic enhancements. Also, the rise in chronic conditions such as osteoarthritis and the aging population's preference for minimally invasive treatments further boost PRP's adoption. Technological advancements in PRP preparation methods and clinical evidence supporting its efficacy continue to boost market expansion.

The integration of PRP into mainstream medical practices and the growing number of clinical studies affirming its therapeutic benefits contribute to sustained market growth. As awareness increases and healthcare providers embrace PRP's potential, the market is poised to continue its upward trajectory globally.

PRP Market Report Highlights

Pure platelet-rich plasma (P-PRP) dominated the market in 2023 due to its high platelet concentration and effectiveness in treating chronic conditions and promoting tissue repair and regeneration.

The general surgery category is estimated to register a highest CAGR, driven by PRP's role in enhancing postoperative recovery and reducing complications, thereby shaping the future of surgical healthcare.

North America dominated the global PRP market in 2023, driven by demand from cosmetic surgeries, orthopedic procedures, and sports injuries, strengthened by arthritis cases and extensive applications.

The global key market players include Vivostat, Arthrex Inc., RegenOrthoSport, Dr. PRP USA LLC, Juventix Regenerative Medical, LLC, Terumo Cardiovascular Systems Corporation, Zimmer Biomet, Isto Biologics, Apex Biologix, and Regen Lab SA.

Polaris Market Research has segmented the platelet rich plasma market report based on type, application, end-use, and region:

PRP Market - Type Outlook (Revenue - USD million, 2019 - 2032)

Pure Platelet-Rich Plasma (P-PRP)
Leukocyte-and Platelet-Rich Plasma (L-PRP)
Pure Platelet-Rich Fibrin (P-PRF) - or Leukocyte-Poor Platelet-Rich Fibrin
Leukocyte- and Platelet-Rich Fibrin (L-PRF)

Platelet Rich Plasma Market - Application Outlook (Revenue - USD million, 2019 - 2032)

Orthopedics
Sports Medicine
General Surgery
Dermatology
Ophthalmology
Neurology
Cardiology
Others

Platelet Rich Plasma Market - End-Use (Revenue - USD million, 2019 - 2032)

Hospitals
Clinics
Others

Platelet Rich Plasma Market - Regional Outlook (Revenue - USD million, 2019 - 2032)

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Australia
Malaysia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa

1. Introduction

1.1 Report Description
- 1.1.1 Objective of the Study
- 1.1.2 Market Scope
- 1.1.3 Assumptions
1.2 Stakeholders

2. Research Methodology

2.1 Research Methodology
2.2 Research Scope and Assumptions
2.3 Information Procurement
- 2.3.1 Purchased Database
- 2.3.2 Internal Database
- 2.3.3 Secondary Sources
- 2.3.4 Third Party Perspective
- 2.3.5 Primary Research
2.4 Information Analysis
- 2.4.1 Data Analysis Models
2.5 Market Formulation and Data Visualization
2.6 Data Validation and Publishing (Secondary Sources)

3. Executive Summary

4. Market Insights

4.1 Platelet Rich Plasma (PRP) - Industry snapshot
4.2 Platelet Rich Plasma (PRP) Market - Value Chain Analysis
- 4.2.1 Platelet Rich Plasma (PRP) Market Dynamics
- 4.2.2 Drivers and Opportunities
  - 4.2.2.1 Rise in demand of PRP in cosmetic surgeries and dermatology
  - 4.2.2.2 Increasing geriatric population, and rise in the occurrence of orthopaedic and sports injuries accelerate the PRP demand over the forecast period
- 4.2.3 Restraints and Challenges
  - 4.2.3.1 High cost of PRP therapy and lack of reimbursement policy may hamper the market growth
4.3 Platelet Rich Plasma (PRP) Market - Porter's Five Forces
- 4.3.1 Threat of Substitutes: (Low to Moderate)
- 4.3.2 Threat of New Entrants: (Moderate to high)
- 4.3.3 Bargaining power of buyers: (Low to Moderate)
- 4.3.4 Bargaining power of suppliers: (Moderate to High)
- 4.3.5 Competitive Rivalry: (Moderate to High)
4.4 Platelet Rich Plasma (PRP) Market - PESTLE Analysis
4.5 Covid-19 Impact Analysis & Industry Trends

5. Platelet Rich Plasma (PRP) Market Assessment by Type

5.1 Introduction
5.2 Pure Platelet-Rich Plasma (P-PRP)
5.3 Leukocyte-and Platelet-Rich Plasma (L-PRP)
5.4 Pure Platelet-Rich Fibrin (P-PRF)
5.5 Leukocyte- and Platelet-Rich Fibrin (L-PRF)

6. Platelet Rich Plasma (PRP) Market Assessment by Application

6.1 Introduction
6.2 Orthopedics
6.3 Sports Medicine
6.4 General Surgery
6.5 Dermatology
6.6 Ophthalmology
6.7 Neurology
6.8 Cardiology
6.9 Others

7. Platelet Rich Plasma (PRP) Market Assessment by End-Use

7.1 Introduction
7.2 Hospitals
7.3 Clinics
7.4 Others

8. Platelet Rich Plasma (PRP) Market Assessment by Region

8.1 Introduction
8.2 Platelet Rich Plasma (PRP) Market - North America
- 8.2.1 North America Blood Plasma, By Type
- 8.2.2 North America Blood Plasma, By Application
- 8.2.3 North America Platelet Rich Plasma (PRP) Market, By End-Use
- 8.2.4 Platelet Rich Plasma (PRP) Market - U.S.
  - 8.2.4.1 U.S. Blood Plasma, By Type
  - 8.2.4.2 U.S. Blood Plasma, By Application
  - 8.2.4.3 U.S. Blood Plasma, By End-Use
- 8.2.5 Platelet Rich Plasma (PRP) Market - Canada
  - 8.2.5.1 Canada Blood Plasma, By Type
  - 8.2.5.2 Canada Blood Plasma, By Application
  - 8.2.5.3 Canada Blood Plasma, By End-Use
8.3 Platelet Rich Plasma (PRP) Market - Europe
- 8.3.1 Europe Blood Plasma, By Type
- 8.3.2 Europe Blood Plasma, By Application
- 8.3.3 Europe Platelet Rich Plasma (PRP) Market, By End-Use
- 8.3.4 Platelet Rich Plasma (PRP) Market - France
  - 8.3.4.1 France Blood Plasma, By Type
  - 8.3.4.2 France Blood Plasma, By Application
  - 8.3.4.3 France Blood Plasma, By End-Use
- 8.3.5 Platelet Rich Plasma (PRP) Market - Germany
  - 8.3.5.1 Germany Blood Plasma, By Type
  - 8.3.5.2 Germany Blood Plasma, By Application
  - 8.3.5.3 Germany Blood Plasma, By End-Use
- 8.3.6 Platelet Rich Plasma (PRP) Market - UK
  - 8.3.6.1 UK Blood Plasma, By Type
  - 8.3.6.2 UK Blood Plasma, By Application
  - 8.3.6.3 UK Blood Plasma, By End-Use
- 8.3.7 Platelet Rich Plasma (PRP) Market - Italy
  - 8.3.7.1 Italy Blood Plasma, By Type
  - 8.3.7.2 Italy Blood Plasma, By Application
  - 8.3.7.3 Italy Blood Plasma, By End-Use
- 8.3.8 Platelet Rich Plasma (PRP) Market - Netherlands
  - 8.3.8.1 Netherlands Blood Plasma, By Type
  - 8.3.8.2 Netherlands Blood Plasma, By Application
  - 8.3.8.3 Netherlands Blood Plasma, By End-Use
- 8.3.9 Platelet Rich Plasma (PRP) Market - Spain
  - 8.3.9.1 Spain Blood Plasma, By Type
  - 8.3.9.2 Spain Blood Plasma, By Application
  - 8.3.9.3 Spain Blood Plasma, By End-Use
- 8.3.10 Platelet Rich Plasma (PRP) Market - Russia
  - 8.3.10.1 Russia Blood Plasma, By Type
  - 8.3.10.2 Russia Blood Plasma, By Application
  - 8.3.10.3 Russia Blood Plasma, By End-Use
- 8.3.11 Platelet Rich Plasma (PRP) Market - Rest of Europe
  - 8.3.11.1 Rest of Europe Blood Plasma, By Type
  - 8.3.11.2 Rest of Europe Blood Plasma, By Application
  - 8.3.11.3 Rest of Europe Blood Plasma, By End-Use
8.4 Platelet Rich Plasma (PRP) Market - Asia Pacific
- 8.4.1 Asia Pacific Blood Plasma, By Type
- 8.4.2 Asia Pacific Blood Plasma, By Application
- 8.4.3 Asia Pacific Platelet Rich Plasma (PRP) Market, By End-Use
- 8.4.4 Platelet Rich Plasma (PRP) Market - Japan
  - 8.4.4.1 Japan Blood Plasma, By Type
  - 8.4.4.2 Japan Blood Plasma, By Application
  - 8.4.4.3 Japan Blood Plasma, By End-Use
- 8.4.5 Platelet Rich Plasma (PRP) Market - China
  - 8.4.5.1 China Blood Plasma, By Type
  - 8.4.5.2 China Blood Plasma, By Application
  - 8.4.5.3 China Blood Plasma, By End-Use
- 8.4.6 Platelet Rich Plasma (PRP) Market - India
  - 8.4.6.1 India Blood Plasma, By Type
  - 8.4.6.2 India Blood Plasma, By Application
  - 8.4.6.3 India Blood Plasma, By End-Use
- 8.4.7 Platelet Rich Plasma (PRP) Market - Malaysia
  - 8.4.7.1 Malaysia Blood Plasma, By Type
  - 8.4.7.2 Malaysia Blood Plasma, By Application
  - 8.4.7.3 Malaysia Blood Plasma, By End-Use
- 8.4.8 Platelet Rich Plasma (PRP) Market - Indonesia
  - 8.4.8.1 Indonesia Blood Plasma, By Type
  - 8.4.8.2 Indonesia Blood Plasma, By Application
  - 8.4.8.3 Indonesia Blood Plasma, By End-Use
- 8.4.9 Platelet Rich Plasma (PRP) Market - South Korea
  - 8.4.9.1 South Korea Blood Plasma, By Type
  - 8.4.9.2 South Korea Blood Plasma, By Application
  - 8.4.9.3 South Korea Blood Plasma, By End-Use
- 8.4.10 Platelet Rich Plasma (PRP) Market - Australia
  - 8.4.10.1 Australia Blood Plasma, By Type
  - 8.4.10.2 Australia Blood Plasma, By Application
  - 8.4.10.3 Australia Blood Plasma, By End-Use
- 8.4.11 Platelet Rich Plasma (PRP) Market - Rest of APAC
  - 8.4.11.1 Rest of APAC Blood Plasma, By Type
  - 8.4.11.2 Rest of APAC Blood Plasma, By Application
  - 8.4.11.3 Rest of APAC Blood Plasma, By End-Use
8.5 Platelet Rich Plasma (PRP) Market - Latin America
- 8.5.1 Latin America Blood Plasma, By Type
- 8.5.2 Latin America Blood Plasma, By Application
- 8.5.3 Latin America Platelet Rich Plasma (PRP) Market, By End-Use
- 8.5.4 Platelet Rich Plasma (PRP) Market - Mexico
  - 8.5.4.1 Mexico Blood Plasma, By Type
  - 8.5.4.2 Mexico Blood Plasma, By Application
  - 8.5.4.3 Mexico Blood Plasma, By End-Use
- 8.5.5 Platelet Rich Plasma (PRP) Market - Brazil
  - 8.5.5.1 Brazil Blood Plasma, By Type
  - 8.5.5.2 Brazil Blood Plasma, By Application
  - 8.5.5.3 Brazil Blood Plasma, By End-Use
- 8.5.6 Platelet Rich Plasma (PRP) Market - Argentina
  - 8.5.6.1 Argentina Blood Plasma, By Type
  - 8.5.6.2 Argentina Blood Plasma, By Application
  - 8.5.6.3 Argentina Blood Plasma, By End-Use
- 8.5.7 Platelet Rich Plasma (PRP) Market - Rest of Latin America
  - 8.5.7.1 Rest of LATAM Blood Plasma, By Type
  - 8.5.7.2 Rest of LATAM Blood Plasma, By Application
  - 8.5.7.3 Rest of LATAM Blood Plasma, By End-Use
8.6 Platelet Rich Plasma (PRP) Market - Middle East Africa
- 8.6.1 Middle East & Africa Blood Plasma, By Type
- 8.6.2 Middle East & Africa Blood Plasma, By Application
- 8.6.3 Middle East & Africa Platelet Rich Plasma (PRP) Market, By End-Use
- 8.6.4 Platelet Rich Plasma (PRP) Market - Saudi Arabia
  - 8.6.4.1 Saudi Arabia Blood Plasma, By Type
  - 8.6.4.2 Saudi Arabia Blood Plasma, By Application
  - 8.6.4.3 Saudi Arabia Blood Plasma, By End-Use
- 8.6.5 Platelet Rich Plasma (PRP) Market - South Africa
  - 8.6.5.1 South Africa Blood Plasma, By Type
  - 8.6.5.2 South Africa Blood Plasma, By Application
  - 8.6.5.3 South Africa Blood Plasma, By End-Use
- 8.6.6 Platelet Rich Plasma (PRP) Market - Rest of MEA
  - 8.6.6.1 Rest of MEA Blood Plasma, By Type
  - 8.6.6.2 Rest of MEA Blood Plasma, By Application
  - 8.6.6.3 Rest of MEA Blood Plasma, By End-Use

9. Competitive Landscape

9.1 Key Market Players: Categorization
9.2 Strategy Framework
9.3 Vendor Landscape
9.4 Strategies Categorization
- 9.4.1 Launch/Approval/Development

10. Company Profiles

10.1 Vivostat
- 10.1.1 Business Overview
- 10.1.2 Products and Services
10.2 Arthrex, Inc.
- 10.2.1 Business Overview
- 10.2.2 Products and Services
- 10.2.3 Recent Developments
10.3 RegenOrthoSport
- 10.3.1 Business Overview
- 10.3.2 Products and Services
10.4 Dr PRP USA LLC
- 10.4.1 Business Overview
- 10.4.2 Products and Services
10.5 Juventix Regenerative Medical, LLC.
- 10.5.1 Business Overview
- 10.5.2 Products and Services
10.6 Terumo Cardiovascular Systems Corporation
- 10.6.1 Business Overview
- 10.6.2 Financial Snapshot
  - 10.6.2.1 Revenue by Geographic Region
- 10.6.3 Products and Services
10.7 Zimmer Biomet
- 10.7.1 Business Overview
- 10.7.2 Financial Snapshot
  - 10.7.2.1 Net Sales by Geographic
  - 10.7.2.2 Net Sales by Product Category
- 10.7.3 Products and Services
- 10.7.4 Recent Developments
10.8 Isto Biologics
- 10.8.1 Business Overview
- 10.8.2 Products and Services
- 10.8.3 Recent Developments
10.9 APEX Biologix
- 10.9.1 Business Overview
- 10.9.2 Products and Services
- 10.9.3 Recent Developments
10.10 Regen Lab SA
- 10.10.1 Business Overview
- 10.10.2 Products and Services

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,250

￦ 6,174,000

PDF (Multi User License)

PDF 보고서를 동일 기업 20명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,250

￦ 7,627,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,250

￦ 9,080,000

※ 부가세 별도